Podcasts about mdr1

We here at NAVAS are excited to bring you a new podcast episode for the new year! And we're starting out our season of the NAVAS podcast with engaging exploration of pharmacogenetics, a groundbreaking field that examines how the genetic makeup of an animal can influence its response to medications. Have you ever had a dog or a cat that took hours, if not days, to finally return to normal after general anesthesia? It's possible that animal had a genetic mutation that altered its metabolic function, causing profound changes in the clinical effects of anesthetic drugs. In this episode, we are joined by veterinary anesthesiologist and overall gene-ius Dr. Tania Perez Jimenez, Assistant Professor of Anesthesia at Washington State University College of Veterinary Medication and head its Pharmacogenetics Laboratory. Dr. Perez Jimenez shares her expertise on the genetic factors that impact anesthesia and pain management in dogs and cats. Together with host, Dr. Bonnie Gatson, they will discuss how genetic variations can affect drug efficacy and safety in individual animals, how you can approach anesthetic management in dog breeds that commonly manifest genetic anomalies such as MDR1 mutations, why we may need to alter the way we utilize Propofol and Alfaxalone in cats and certain dog breeds, and how we could all benefit from going to more cat shows.Explore more information discussed on this podcast at the WSU Pharmacogenetics Laboratory website.If you like what you hear, we have a couple of favors to ask of you:Become a member of NAVAS for access to more anesthesia and analgesia educational and RACE-approved CE content.Spread the word. Share our podcast on your socials or a discussion forum. That would really help us achieve our mission: Reduce mortality and morbidity in veterinary patients undergoing sedation, anesthesia, and analgesia through high-quality, peer-reviewed education.Thank you to our sponsor, Dechra - learn more about the pharmaceutical products Dechra has to offer veterinary professionals, such as Zenalpha.If you have questions about this episode or want to suggest topics for future episodes, reach out to the producers at education@mynavas.org.All opinions stated by the host and their guests are theirs alone and do not represent the thoughts or opinions of any corporation, university, or other business or governmental entity.

We do everything to help our feline friends, so it's heartbreaking when a medication…

We do everything to help our feline friends, so it's heartbreaking when a medication that's meant to help ends up being life-threatening. Ingredients like eprinomectin [epp-rin-oh-MEC-tin], ivermectin [eye-ver-MEC-tin], selamectin [sell-ah-MEC-tin]...

1976: Schwedens König Carl Gustav heiratet die deutsche Silvia Sommerlath und Pussycat feiern mit "Mississippi" ihren größten Hit.

贊助我們做更好的內容：https://pay.firstory.me/user/ck4fgb04n698h0804wzdkaycj

MDR1 Defekt by Leine ab und leben

Iscriviti alla pagina Facebook► https://www.facebook.com/laboratoriolavallonea/Visita il Blog► http://www.mylav.net/

Background: Prolactinomas are the most frequent pituitary adenomas. The treatment with cabergoline, the most common dopamine agonist used, is associated with side effects such as nausea, vomiting, dizziness, headaches, movement disorders and fatigue. There is some additional evidence from case reports and small studies that some patients report neuropsychiatric side effects such as depression, gambling, hypersexuality and impulsive control disorders. Objective: In this cross-sectional study we sought to investigate the baseline clinical, demographic and disease characteristics of our patient group as well as life-time comorbidities. Additionally, side effects under treatment with cabergoline (prevalence and enhancement) and whether genetic variants of the ABCB1 gene (coding MDR1 or P-gp) could account for difference in the central neuropsychiatric side effects were investigated. Methods: Questionnaires evaluating medical history, therapy side effects and further demographic characteristics were sent to all prolactinoma patients currently treated at the Max Planck Institute of Psychiatry in Munich. Additionally, DNA extracted either from blood or saliva samples was genotyped for each patient. Results: The clinical study included a total of 92 patients (23 male and 69 female, macro-to-microadenoma-ratio 1:1). The mean age of our group at the time of the study was 49,2 ± 13,8 years. Of the 79 patients treated with cabergoline, the following side effects associated with treatment were more prominent: fatigue (n=35), headaches (n=26), depressed mood (n=26), sleep disorders (n=26), dizziness (n=22), aggressiveness (n=17), anxiety (n=19) and weight loss (n=16). 18 patients reported of decreased and 16 of increased libido. Significant effects were observed for the C-carriers and heterozygous CT-individuals of rs1045642 that presented less frequent fatigue and sleep disorders under cabergoline. In the analysis of SNP rs2032582, G-carriers seemed to be protected from enhancement of dizziness under cabergoline. SNPs rs2235015 and rs2032583 were found to have no association with the examined symptoms. Conclusion: In our group we described an increased prevalence of symptoms such as fatigue and weight loss under cabergoline, as well as neuropsychiatric side effects such as depressed mood, aggressiveness and anxiety in comparison to the available data of the literature. We demonstrated that polymorphisms of SNPs rs1045642 and rs2032582 of the ABCB1 gene predispose for fatigue, sleep disorders and dizziness under cabergoline. This is the first study demonstrating that individual ABCB1 gene polymorphisms could account for a different occurrence or enhancement of central side effects of this systematically administered medication.

Beim MDR1 Defekt entwickeln Tiere eine Über-Empfindlichkeit gegen bestimmte Medikamente. Ursache ist ein fehlerhaftes Gen. Mehr zu MDR1 im Podcast.

In gene therapy, a clinically relevant therapeutic effect requires long-term expression of the desired gene at a level sufficient to correct or at least alleviate the underlying gene defect. One approach to achieve persistent as well as high-level transgene expression in a significant percentage of target cells would be to select cells expressing both the desired transgene and a linked selectable gene such as the human multi-drug resistance (MDR1) gene-in a bicistronic vector. Because of its accessibility, the skin is a very attractive target tissue to select genetically modified cells, allowing topical application of a selecting agent, thus minimizing potential toxic side effects. Among the potential selecting drugs, agents that block cell division, such as colchicine, are of particular interest because the use of anti-mitotic drugs takes advantage of the rapid keratinocyte ( KC) turnover in the epidermis and the need for continued proliferation to substitute the KC lost due to selection. Before assessing the therapeutic benefit of such an approach, several key questions need to be answered in preclinical models: ( 1) Does topical colchicine application achieve the desired in vivo effect by blocking KC mitosis without eliciting unwanted toxic side effects? ( 2) Are MDR-transduced (MDR+) human KC still able to proliferate and differentiate when treated with colchicine? ( 3) Can MDR+ KC be enriched by topical selection? ( 4) Does topical selection result in persistent transgene expression by selecting KC stem cells expressing MDR? To answer these questions and to test the feasibility of such an approach both an in vitro skin equivalent and an in vivo human skin graft model were developed in which MDR+ KC were treated with different dosages of colchicine. Quantitative and qualitative analyses of MDR expression in human KC showed that topical colchicine treatment selects high-level transgene expression in a high percentage of KC. Moreover, determination of transgene copy numbers demonstrated that MDR+ KC progenitor cells were enriched by topical selection resulting in long-term expression of the transgene in the skin. Thus, in summary, these models demonstrate that topical selection of MDR+ KC is a safe approach to efficiently enhance long-term gene expression in the skin and holds future promise for clinical gene therapy applications. Copyright (C) 2004 S. Karger AG, Basel.